Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 25, 2013

Orexo, AstraZeneca Pick Up Where Janssen Left Off

  • Orexo and AstraZeneca have partnered to advance Orexo's OX-CLI, a preclinical program for a potential treatment of respiratory diseases. OX-CLI—along with OX-ESI (another arachidonic acid-based advanced preclinical program) and a third, undisclosed Janssen Pharmaceutical program—had previously been the focus of a collaboration between Orexo and Janssen inked in June of 2010, one that potentially would have been worth over $595 million had it not been terminated one year ago. 

    Orexo is granting AstraZeneca rights to conduct further preclinical research and evaluation of compounds in the OX-CLI program. AstraZeneca also has an option to acquire the compounds pertaining to the program, under which Orexo will receive development milestones and royalties on future revenues.

    “Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients,” says Orexo CEO Anders Lundström. “AstraZeneca, a leading global company within the inflammatory and respiratory area, is the optimal partner for OX-CLI and we look forward to see the project advancing.”



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »